Τίτλος:
Clinical significance of organ- and non-organ-specific autoantibodies on
the response to anti-viral treatment of patients with chronic hepatitis
C
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background Development of organ- and non-organ-specific autoantibodies
has been reported in hepatitis C virus patients treated with
interferon-alpha plus/minus ribavirin.
Aims To address whether prevalence and the titre of gastric parietal
autoantibodies and non-organ-specific autoantibody in hepatitis C
virus-treated patients were affected by therapy, and if the development
of these antibodies carries any clinical significance on the response to
treatment, as few studies in adults have been strictly designed to
address the above hypothesis.
Methods Samples at three time-points (baseline, end of treatment, end of
followup) from 102 hepatitis C virus patients (39 sustained responders,
26 relapsers, 33 non-responders; four lost in follow-up) were studied
for gastric parietal autoantibodies and/or non-organ-specific
autoantibody by indirect immunofluorescence, commercial and in-house
enzyme-linked immunosorbent assays.
Results Sustained virological and biochemical response was associated
with antinuclear antibody absence (end of treatment or end of
follow-up), decrease of smooth-muscle antibody titres during therapy and
gastric parietal autoantibodies negativity at baseline. However, after
multivariate analysis only antinuclear antibody positivity at the end of
treatment and increase of smooth-muscle antibody titres were associated
with worst treatment response, independently of known factors of worst
treatment outcome.
Conclusions We were able to demonstrate a negative correlation between
the efficacy of anti-viral treatment for hepatitis C virus and the
presence of antinuclear antibody and smooth-muscle antibody before
treatment, or their increase during therapy.
Συγγραφείς:
Gatselis, N. K.
Georgiadou, S. P.
Koukoulis, G. K. and
Tassopoulos, N.
Zachou, K.
Liaskos, C.
Hatzakis, A. and
Dalekos, G. N.
Περιοδικό:
Alimentary Pharmacology & Therapeutics
DOI:
10.1111/j.1365-2036.2006.03165.x
